Literature DB >> 17942081

Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms.

Lisbeth K Siddens1, Marilyn C Henderson, Jonathan E Vandyke, David E Williams, Sharon K Krueger.   

Abstract

The significance of active versus inactive flavin-containing monooxygenase 2 (FMO2) for human drug and xenobiotic metabolism and sensitivity is unknown, but the underlying ethnic polymorphism is well documented. We used quantitative real-time PCR to measure message levels of Fmo1, Fmo2, Fmo3 and Fmo5 in lung and liver from eight strains of 8 week old female mice to determine if a strain could be identified that predominately expressed Fmo2 in lung, recapitulating the human FMO expression profile and being the ideal strain for Fmo2 knockout studies. We also characterized enzyme activity of baculovirus expressed mouse Fmo1, Fmo2 and Fmo3 to identify a substrate or incubation conditions capable of discriminating Fmo2 from Fmo mixtures. Fmo transcript expression patterns were similar for all strains. In lung, 59% of total FMO message was Fmo2, but Fmo1 levels were also high, averaging 34%, whereas Fmo3 and Fmo5 levels were 2 and 5%, respectively. In liver, Fmo1, Fmo2, Fmo3 and Fmo5 contributed 16, 1, 7 and 76% respectively, of detected message. Peak activity varied by isoform and was pH- and substrate-dependent. Fmo3 oxidation of methyl p-tolyl sulfide was negligible at pH 9.5, but Fmo3 oxidation of methimazole was comparable to Fmo1 and Fmo2. Heating microsomes at 50 degrees C for 10min eliminated most Fmo1 and Fmo3 activity, while 94% of Fmo2 activity remained. Measurement of activity in heated and unheated lung and liver microsomes verified relative transcript abundance. Our results show that dual Fmo1/2 knockouts will be required to model the human lung FMO profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942081      PMCID: PMC2293301          DOI: 10.1016/j.bcp.2007.09.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  33 in total

1.  Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein.

Authors:  Sharon K Krueger; Sarah R Martin; Mei-Fei Yueh; Clifford B Pereira; David E Williams
Journal:  Drug Metab Dispos       Date:  2002-01       Impact factor: 3.922

2.  The FMO2 gene of laboratory rats, as in most humans, encodes a truncated protein.

Authors:  Virginie Lattard; Christiane Longin-Sauvageon; Sharon K Krueger; David E Williams; Etienne Benoit
Journal:  Biochem Biophys Res Commun       Date:  2002-03-29       Impact factor: 3.575

3.  Characterization of expressed full-length and truncated FMO2 from rhesus monkey.

Authors:  S K Krueger; M F Yueh; S R Martin; C B Pereira; D E Williams
Journal:  Drug Metab Dispos       Date:  2001-05       Impact factor: 3.922

4.  Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1.

Authors:  Y M Kim; D M Ziegler
Journal:  Drug Metab Dispos       Date:  2000-08       Impact factor: 3.922

5.  Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters.

Authors:  Diana Hernandez; Azara Janmohamed; Pritpal Chandan; Ian R Phillips; Elizabeth A Shephard
Journal:  Pharmacogenetics       Date:  2004-02

6.  Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Authors:  Ronald N Hines; Kathleen A Hopp; Jose Franco; Kia Saeian; Frank P Begun
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

7.  Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin-dependent monooxygenase 3.

Authors:  P Blaise Smith; Charles Crespi
Journal:  Biochem Pharmacol       Date:  2002-06-01       Impact factor: 5.858

Review 8.  Genetic polymorphisms of flavin-containing monooxygenase (FMO).

Authors:  Sharon K Krueger; David E Williams; Mei-Fei Yueh; Sarah R Martin; Ronald N Hines; Judy L Raucy; Colin T Dolphin; Elizabeth A Shephard; Ian R Phillips
Journal:  Drug Metab Rev       Date:  2002-08       Impact factor: 4.518

9.  Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.

Authors:  Bjarte Furnes; Jinong Feng; Steve S Sommer; Daniel Schlenk
Journal:  Drug Metab Dispos       Date:  2003-02       Impact factor: 3.922

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  10 in total

1.  Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Andrew Advani; Qingling Huang; Kerri Thai; Suzanne L Advani; Kathryn E White; Darren J Kelly; Darren A Yuen; Kim A Connelly; Philip A Marsden; Richard E Gilbert
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  The tissue-specific toxicity of methimazole in the mouse olfactory mucosa is partly mediated through target-tissue metabolic activation by CYP2A5.

Authors:  Fang Xie; Xin Zhou; Mary Beth Genter; Melissa Behr; Jun Gu; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2011-03-17       Impact factor: 3.922

3.  Flavin-containing monooxygenase mRNA levels are up-regulated in als brain areas in SOD1-mutant mice.

Authors:  Stella Gagliardi; Paolo Ogliari; Annalisa Davin; Manuel Corato; Emanuela Cova; Kenneth Abel; John R Cashman; Mauro Ceroni; Cristina Cereda
Journal:  Neurotox Res       Date:  2010-11-17       Impact factor: 3.911

4.  Aryl hydrocarbon receptor-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver.

Authors:  Trine Celius; Steven Roblin; Patricia A Harper; Jason Matthews; Paul C Boutros; Raimo Pohjanvirta; Allan B Okey
Journal:  Drug Metab Dispos       Date:  2008-09-02       Impact factor: 3.922

5.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Authors:  Sharon K Krueger; Marilyn C Henderson; Lisbeth K Siddens; Jonathan E VanDyke; Abby D Benninghoff; P Andrew Karplus; Bjarte Furnes; Daniel Schlenk; David E Williams
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

6.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

7.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

8.  Flavin-Containing Monooxygenases Are Conserved Regulators of Stress Resistance and Metabolism.

Authors:  Shijiao Huang; Marshall B Howington; Craig J Dobry; Charles R Evans; Scott F Leiser
Journal:  Front Cell Dev Biol       Date:  2021-02-12

9.  Brown adipose tissue dysfunction promotes heart failure via a trimethylamine N-oxide-dependent mechanism.

Authors:  Yohko Yoshida; Ippei Shimizu; Atsuhiro Shimada; Keita Nakahara; Sachiko Yanagisawa; Minoru Kubo; Shinji Fukuda; Chiharu Ishii; Hiromitsu Yamamoto; Takamasa Ishikawa; Kuniyuki Kano; Junken Aoki; Goro Katsuumi; Masayoshi Suda; Kazuyuki Ozaki; Yutaka Yoshida; Shujiro Okuda; Shigeo Ohta; Shiki Okamoto; Yasuhiko Minokoshi; Kanako Oda; Toshikuni Sasaoka; Manabu Abe; Kenji Sakimura; Yoshiaki Kubota; Norihiko Yoshimura; Shingo Kajimura; Maria Zuriaga; Kenneth Walsh; Tomoyoshi Soga; Tohru Minamino
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

10.  Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse.

Authors:  Amy L Palmer; Virginia L Leykam; Andrew Larkin; Sharon K Krueger; Ian R Phillips; Elizabeth A Shephard; David E Williams
Journal:  Pharmaceuticals (Basel)       Date:  2012
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.